Day One Biopharmaceuticals has entered into a Cooperative Research and Development Agreement with NCI’s Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program to expand therapeutic research opportunities using DAY101 (tovorafenib).
“Yesterday, I went to sleep as acting NCI director, and this morning, as I woke up, I have a new boss, Monica Bertagnolli,” Douglas R. Lowy said in the morning of Oct. 3, addressing a well-caffeinated meeting of the Association of American Cancer Institutes.
According to the NCI study, the number of people who live outside the catchment areas of NCI-designated cancer centers is estimated at about 40 million. According to the AACI-Jefferson study, the number of people who live outside catchment areas of the AACI member cancer centers is estimated at about 25 million.
Oct. 3 was Monica M. Bertagnolli’s first day on the job as the 16th director of the National Cancer Institute.
Up to 15% of U.S. counties—home to about 25 million Americans—fall outside the reach of the catchment area of this country’s cancer centers.
NCI has renewed UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center Kidney Cancer Program Specialized Program of Research Excellence award.
Drawing on Charles Dickens, NCI Acting Director Douglas Lowy has a teaching moment for oncology: we live in the best of times as well as the worst of times, because only fragments of human society—both in the United States and in low- and middle-income countries—fully benefit from modern cancer care.
The St. Jude Children’s Research Hospital Comprehensive Cancer Center has received a Merit Extension Award from the NCI, extending the center’s current $35 million, five-year Cancer Center Support Grant for an additional two years.
The 2024 Bypass Budget submitted by NCI Acting Director Douglas Lowy asks for $9.988 billion—$2.222 billion more than the 2023 document submitted by then director Ned Sharpless.
NCI has awarded a five-year, $13.3 million grant to a collaborative study on sequential combinations of targeted inhibitors and immunotherapies against cancer.